SCHEMBL2386900

SCHEMBL2386900

N#Cc1[nH]ncc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28953511 0.73
SCHEMBL279669 0.71
SCHEMBL4834838 0.71
SCHEMBL16654249 0.67
SCHEMBL20552561 0.63 AXL (0.38)
SCHEMBL22445339 0.62
SCHEMBL256092 0.62
SCHEMBL2009063 0.62 METAP2 (0.56)
SCHEMBL15265822 0.62 NOS1 (0.50)
SCHEMBL31639077 0.62 NOS1 (0.34)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3800186-B1 CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER MISSION THERAPEUTICS LTD (GB) 2024-10-02 EP disclosed
US-11319287-B2 Cyanopyrrolidines as dub inhibitors for the treatment of cancer MISSION THERAPEUTICS LIMITED (GB) 2022-05-03 US disclosed
CN-107849013-B Cyanopyrrolidines as DUB inhibitors for the treatment of cancer 特殊治疗有限公司 2022-03-29 CN disclosed
EP-3800186-A1 CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER Mission Therapeutics Limited (GB) 2021-04-07 EP disclosed
EP-3800186-A1 CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER Mission Therapeutics Limited (GB) 2021-04-07 EP disclosed
CN-107001278-B Tetrahydroisoquinoline derivatives UCB生物制药私人有限公司 2020-11-24 CN disclosed
US-20200231542-A1 CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER MISSION THERAPEUTICS LIMITED (GB) 2020-07-23 US disclosed
EP-3204359-B1 TETRAHYDROISOQUINOLINE DERIVATIVES UCB Biopharma SRL (BE) 2020-07-01 EP disclosed
US-10669234-B2 Cyanopyrrolidines as dub inhibitors for the treatment of cancer MISSION THERAPEUTICS LIMITED (GB) 2020-06-02 US disclosed
EP-3322702-B1 CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER MISSION THERAPEUTICS LTD (GB) 2019-11-20 EP disclosed
EP-2215085-B1 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2011-09-07 EP disclosed
CN-101910158-A Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders ASTRAZENECA AB 2010-12-08 CN disclosed
EP-2215085-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS AstraZeneca AB (SE) 2010-08-11 EP disclosed
US-20100197678-A1 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-08-05 US disclosed
CN-101547909-A Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof BOEHRINGER INGELHEIM INT (DE) 2009-09-30 CN disclosed
EP-2102170-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF Boehringer Ingelheim International GmbH (DE) 2009-09-23 EP disclosed
US-20090118305-A1 PYRIDINE AND PYRAZINE DERIVATIVES - 083 ASTRAZENECA AB (SE) 2009-05-07 US disclosed
WO-2009053737-A2 PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS ASTRAZENECA AB (SE) 2009-04-30 WO disclosed
WO-2008070507-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-12 WO disclosed
WO-2008070507-A2 GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-12 WO disclosed